NEW YORK (GenomeWeb News) – Abcodia today said that it will collaborate with Singapore-based VolitionRx on developing biomarker-based tests for a variety of cancers.
The London-based firm said that the partnership will discover and develop diagnostic tests for lung, colorectal, and pancreatic cancer using VolitionRx's nucleosome technology. Abcodia said that it will work with VolitonRx on designing the program and identifying cohort samples from its large prospective serum biobank.
"Access to Abcodia's samples will potentially expedite the development of our blood-based diagnostic technology, Nucleosomics," VolitonRx CEO Cameron Reynolds said in a statement. "We believe that data from validation of thousands of samples, across multiple cancer areas, will help us to reach our goal of applying for European CE Mark approval this year."
Further terms of the alliance were not disclosed.